This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Review of GSK-Pfizer consumer-healthcare deal in Australia kicks off

By Jet Damazo-Santos ( February 28, 2019, 02:18 GMT | Insight) -- The plan by GlaxoSmithKline and Pfizer to combine their rival consumer-healthcare businesses will go under Australia’s informal review process starting today, with the country’s antitrust regulator keen on analyzing the importance of the Panadol, Voltaren and Advil brands as well as the supply chain for over-the-counter medicines.The plan by GlaxoSmithKline and Pfizer to combine their rival consumer-healthcare businesses will go under Australia’s informal-review process starting today, with the country’s antitrust regulator keen on analyzing the importance of the Panadol, Voltaren and Advil brands as well as the supply chain for over-the-counter medicines....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login